Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
Zacks News
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Patterson Companies' (PDCO) New Launch to Boost Patient Service
by Zacks Equity Research
Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
by Zacks Equity Research
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $75.57, marking a +0.76% move from the previous day.
Envista (NVST) Down 4.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
by Zacks Equity Research
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in kidney care.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
by Zacks Equity Research
Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.
Reasons Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Stryker (SYK) Issues Safety Notice for Its Total Knee System
by Zacks Equity Research
Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Intuitive Surgical (ISRG) Stock Gains 20% YTD: Here's Why
by Zacks Equity Research
Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.
Inari Medical (NARI) Sues Truvic on Patent Infringement
by Zacks Equity Research
Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.
Integer Holdings (ITGR) Gains 23.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares soar on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
by Zacks Equity Research
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC), Cityblock Partner to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Cityblock to provide comprehensive care services to Central Florida's Medicaid members.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock.